Advertisement

Gammopathy pp 199-204 | Cite as

Prognosis and epidemiology of plasmocytomas

  • János Jákó

Abstract

The introduction of the alkylating agents was a milestone in the therapy and prolongation of the post-diagnosis survival of the patients with plasmocytoma. The survival rate has been expanded from 6–12 months (32, 57) to 30–36 months (29). Numerous other monoand polychemotherapy protocols failed to statistically significantly further prolong the survival rate (3, 9). The promising exceptionally beneficial results of some schemes could not, however, be adequately controlled. The analysis of the beneficial results and fiascos made the specialists first to look for a single (?) factor responsible for the prolongation of the survival rate and then to determine those clinical and laboratory tests, which can be applied for the evaluation of the tumour mass.

Keywords

Multiple Myeloma Plasma Cell Plasma Cell Myeloma Smouldering Multiple Myeloma Tiple Myeloma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexanian, R., Balberzak, S., Bonnet, J. D., Geham, E. A. Haut, A., Hewlett, J. S., Monto, R. W. Prognostic factors in multiple myeloma. Cancer. 36, 1192. 1975.PubMedCrossRefGoogle Scholar
  2. 2.
    Alexanian, R. Localised and indolent myeloma. Blood. 56, 521. 1980.PubMedGoogle Scholar
  3. 3.
    Alexanian, R., Dreicer, R. Chemotherapy for multiple myeloma. Cancer. 55, 583. 1984.CrossRefGoogle Scholar
  4. 4.
    Alexanian, R. Treatment of multiple myeloma. Acta Haematol. 63, 237. 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Barlogie, B., Latrielle, J., Alexanian, R., Swartzengruber, D. E.,Smallwood, L., Maddox, A. M., Raker, M. N., Drewinko, B. Quantitative cytology in myeloma research. Clin. Haematol. 11, 19. 1982.PubMedGoogle Scholar
  6. 6.
    Bartl, R., Frisch, B., Burkhardt, R. Multiple myeloma. Bone Marrow Biopsies Revisited. Karger. Basel. 42. 1982.Google Scholar
  7. 7.
    Bartl, R., Frisch, B., Burkhardt, R., Fateh- Moghadam, A., Mahl, G., Gierster, P., Sund, M., Kettner, G. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Brit. J. Haematol. 51, 361. 1982.CrossRefGoogle Scholar
  8. 8.
    Bataille, R., Durie, B. G. M., Grenier, J. Serum béta-2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Brit. J. Haematol. 55, 439. 1983.CrossRefGoogle Scholar
  9. 9.
    Bergsagel, D. E. Progress in the treatment of plasma cell myeloma. J. Clin. Oncol. 1,510. 1983.PubMedGoogle Scholar
  10. 10.
    Bergsagel, D. E. Prognostic factors in plasma cell myeloma. Eur. J. Canc. Clin. Oncol. 19, 1493. 1983.Google Scholar
  11. 11.
    Bettini, R., Steidl, L., Rapazzani, P., Giardina, G. Prognostic value of the staging system proposed by Merlini, Waldenström and Jayakar for multiple myeloma. Acta Haematol. 70, 378. 1983.CrossRefGoogle Scholar
  12. 12.
    Blattner, W. A. Epidemiology of multiple myeloma and related plasma cell disorders: an analytic review. In: Progress in myeloma. Ed: by Potter, M. Elsevier North-Holland. N. Y. 1, 1980.Google Scholar
  13. 13.
    Boccadoro, M., Gavarotti, P., Fossati, L. Pileri, A., Marmont, F., Nerotto, G., Gallamino, A., Volta, C, Tribalto, M., Testa, M. G., Amadori, S., Mandelli, F., Durie, B.G.M. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a relable indicator of patients not requiring therapy. Brit. J. Haematol. 58, 689. 1984.CrossRefGoogle Scholar
  14. 14.
    Boga, Marianna, Jákó, J., Domán, J., Magyar, Éva, Konyár, E. Familial myeloma. Folia Haematol. 3, 201. 1973.Google Scholar
  15. 15.
    Bourguet, C. Claire, Grufferman, S., Delzell, Elizabeth, DeLong, R. Elizabeth, Cohen, H. J. Multiple myeloma and family history of cancer. Cancer. 56, 2133. 1985.PubMedCrossRefGoogle Scholar
  16. 16.
    Buckman, R., Guzick, J., Galton, D. A. G. Long term survival in myelomatosis. Brit. J. Haematol. 52, 589. 1982.CrossRefGoogle Scholar
  17. 17.
    Bunn, P. A., Krasnow, S., Makuch, R. W., Selam, M. L., Schechter, G. P. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications. Blood. 59, 528. 1982.PubMedGoogle Scholar
  18. 18.
    Burmeister, L. F., Burmeister G. D., Van Lier, S. F., Isacson, P. Selected cancer mortality and farm practices in Iowa. Amer. J. Epidemiol. 118, 72. 1983.Google Scholar
  19. 19.
    Cavo, V., Baccarani, M., Gobbi, A. Lipizer, A., Tura, S. Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma. Brit. J. Haematol. 55, 683. 1983.CrossRefGoogle Scholar
  20. 20.
    Cuzick, J. Radiation-induced myelomatosis. N. Engl. J. Med. 304, 204. 1981.PubMedCrossRefGoogle Scholar
  21. 21.
    Cuzick, J., Velez, R., Doll, R. International variations and temporal trends in mortality from multiple myeloma. Internat. J. Cancer. 32, 13. 1983.CrossRefGoogle Scholar
  22. 22.
    Decoufle, P., Stanislawczyk, K., Houten, L. A retrospective survey of cancer in relation to occupation. DHEW (NIOSH) Publication. 77, 1977.Google Scholar
  23. 23.
    Dorken, H., Vollmer, I. The epidemiology of multiple myeloma — investigation of 149 cases. Arch. Geschwulstforsch. 31, 18. 1968.PubMedGoogle Scholar
  24. 24.
    Drewinko, B., Alexanian, R., Boyer, H. The growth fraction of human myeloma cells. Blood. 57, 333. 1981.PubMedGoogle Scholar
  25. 25.
    Durie, B. G. M., Salmon, S. E. A clinical staging system for multiple myeloma. Cancer. 36, 842. 1975.PubMedCrossRefGoogle Scholar
  26. 26.
    Durie, B. G. M., Salmon, S. E., Moon, T. E. Pretreatment tumour mass, cell kinetics and prognosis in multiple myeloma. Blood. 55, 364. 1980.PubMedGoogle Scholar
  27. 27.
    Durie, B. G. M., Salmon, S. E., Murdy, G. R. Relation of osteoclast growth: interrelationships between drug sensitivity, cell kinetics and activating factor production to extent of bone disease in multiple patient survival duration. Blood. 61,929. 1981.Google Scholar
  28. 28.
    Durie, B. G. M. Staging and kinetics of multiple myeloma. Clinics in Haematol. 11,3. 1982.Google Scholar
  29. 29.
    Durie, B. G. M., Salmon, S. E. The current status and future prospects of treatment for multiple myeloma. Clinics in Haematol. 11, 181. 1982.Google Scholar
  30. 30.
    Durie, B. G. M., Young, L. A., Salmon, S. E. Human myeloma in vitro colony myeloma.Brit. J. Haematol. 47, 21. 1983.CrossRefGoogle Scholar
  31. 31.
    Endo, T., Okumura, H., Kikuchi, K., Munakata, J., Otake, M., Nomura, T., Asakawa, H. Immunoglobulin E (IgE) multiple myeloma. A case report and review of the literature. Amer. J. Med. 70, 1127. 1981.PubMedCrossRefGoogle Scholar
  32. 32.
    Feinleib, M., MacMahon, B. Duration of survival in multiple myeloma. J. Nat. Cancer Inst. 24, 1259. 1960.PubMedGoogle Scholar
  33. 33.
    Fritz, E., Ludwig, H., Kundi, M. Prognostic relevance of cellular morphology in multiple myeloma. Blood. 63, 1072. 1984.PubMedGoogle Scholar
  34. 34.
    Gassmann, W., Pralle, H., Haferlach, T., Pandurevič, S., Graubner, M., Schmitz, N., Loffler, H. Staging system for multiple myeloma: a comparison. Brit. J. Haematol. 59, 703. 1968.CrossRefGoogle Scholar
  35. 35.
    Grepp, P. R., Raymond, N. M., Kyle, R. A., O’Fallon, W. M. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 63, 305. 1985.Google Scholar
  36. 36.
    Gramont, A., Benitez, O., Smadja, N., Brissand, P., Sirenelli, A., Hubert, D., Krulik, M., Debray, J. Bone marrow plasma cell infiltration in multiple myeloma. Brit. J. Haematol. 57, 351. 1984.Google Scholar
  37. 37.
    Hamburger, A. W., Salmon, S. E. Primary bioassay of human myeloma stem cells. J. Clin. Invest. 60, 846. 1977.PubMedCrossRefGoogle Scholar
  38. 38.
    Hobbs, J. R. Growth rates and response to treatment in human myelomatosis. Brit. J. Haematol. 16, 607. 1969.CrossRefGoogle Scholar
  39. 39.
    Hoffman, V., Salmon, S. E., Durie, B. G. M. Drug resistance in multiple myeloma associated with high in vitro incorporation of 3(H) thymidine. Blood. 58,471. 1981.Google Scholar
  40. 40.
    Ichimaru, M., Ishimaru, T., Mikami, M. Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki by dose 1950–1976. Radiation Effects Research Report, Technical Report. 9. 1979.Google Scholar
  41. 41.
    Isomaki, H. A., Hakulinen, T.;Joutsenlahti, U. Excess risk of lymphoma, leukaemia and myeloma in patients with rheumatoid arthritis. J. Chronic. Dis. 31,691. 1978.PubMedCrossRefGoogle Scholar
  42. 42.
    Jancelwiez, Z., Talatsuki, K., Sugai, S., Pruzanski, W. IgD multiple myeloma. Arch. Intern. Med. 135, 87. 1975.CrossRefGoogle Scholar
  43. 43.
    Jákó, J., Virágh, Sz., Schopper, J., Sebők, J., Juhász, J. Nierenerkrankungen bei monoclonalen Gammopathien — eineklinisch-pathologische Studie. Immun. Infekt. 9,60. 1981.PubMedGoogle Scholar
  44. 44.
    Kyle, R. A. Multiple myeloma: a review of 869 cases. Mayo Clinic Proc. 50, 29. 1975.Google Scholar
  45. 45.
    Kyle, R. A.,Grepp, P. R. Smouldering multiple myeloma. N. Engl. J. Med. 302, 1374. 1980.Google Scholar
  46. 46.
    Kyle, R. A. Long term survival in multiple myeloma. N. Engl. J. Med. 308, 314. 1983.PubMedCrossRefGoogle Scholar
  47. 47.
    Lee, B. J., Myers, J. Long term survival in myeloma. N. Engl. J. Med. 308, 243. 1983.Google Scholar
  48. 48.
    Liang, W., Hopper, J. E., Rowley, J. D. Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinaemic diseases. Cancer. 44, 630. 1979.PubMedCrossRefGoogle Scholar
  49. 49.
    Matzner, Y., Benbassat, J., Polliack, A. Prognostic factors in multiple myeloma. Acta Haematol. 60, 257. 1978.PubMedCrossRefGoogle Scholar
  50. 50.
    Merlini, G., Waldenström, J. G., Jayakar, S. D. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood. 55, 1011, 1980.PubMedGoogle Scholar
  51. 51.
    Milham,S. Leukemia and multiple myeloma in farmers. Amer. J. Epidemiol. 94, 307. 1971.Google Scholar
  52. 52.
    Milham, S. Occupational mortality in Washington State, 1950–1971. DHEW (NIOSH) Publication 76, 1976.Google Scholar
  53. 53.
    MRC Working Party on Leukaemia in Adults. Report on the first myelomatosis trial. part 1. Analysis of presenting features of prognostic importance. Brit. J. Haematol. 24, 123. 1973.CrossRefGoogle Scholar
  54. 54.
    MRC Working Party of Leukaemia in Adults. Prognostic features in the third myelomatosis trial. Brit. J.Cancer. 42, 831. 1980.CrossRefGoogle Scholar
  55. 55.
    Nathans, D., Fahey, J. L., Potter, M. The formation of myeloma protein by a mouse plasma cell tumour. J. Exp. Med. 108, 121. 1958.PubMedCrossRefGoogle Scholar
  56. 56.
    Norfolk, D., Child, J. A., Cooper, E. H., Kerruish, S., Milford Ward, A. Serum beta-2 microglobulin in myelomatosis; potential value in stratification and monitoring. Brit. J. Cancer. 42,510. 1980.PubMedCrossRefGoogle Scholar
  57. 57.
    Osgood, E. E. The survival time of patients with plasmacytic myeloma. Cancer Chemotherapy Reports. 9, 1. 1960.Google Scholar
  58. 58.
    Osmond, C, Gardner, M. J. Age, period and cohort models applied to cancer mortality rates. Statistical Medicine. 1, 245. 1982.CrossRefGoogle Scholar
  59. 59.
    Otieno, L. S., Ogada, T. Multiple myeloma at Kenyatta National Hospital, 1973–1976. East African Med. J. 54, 574. 1977.Google Scholar
  60. 60.
    Salmon, S. E., Smith, B. A. Immunoglobulin synthesis and total body tumour cell number in IgG multiple myeloma. J. Clin. Invest. 49, 1114. 1970.PubMedCrossRefGoogle Scholar
  61. 61.
    Salmon, S. E., Hamburger, A. W., Soehnlen, B. J., Durie, B. G. M., Alberts, D. S., Moon, T. E. Quantitation of differential sensitivity of human tumour stem cells to anticancer drugs. N. Engl. J. Med. 298, 1321. 1978.PubMedCrossRefGoogle Scholar
  62. 62.
    Salmon, S. E. Cloning and chemosensitivity of myeloma stem cells. Clin. Haematol. 11, 47. 1982.PubMedGoogle Scholar
  63. 63.
    Scarffe, H., Anderson, H., Palmer, M. K., Crowther, D. Prognostic significance of pretreatment serum beta-2 microglobulin levels in multiple myeloma. Eur. J. Cancer Clin. Oncol. 19, 1361. 1983.PubMedCrossRefGoogle Scholar
  64. 64.
    Schur, P. H., Kyle, R. A., Block, K. J., Hammack, W. J., Rivers, S. L., Sargent, A., Ritchie, R. F., McIntyre, O. R., Moloney, W. C, Wolfson, L. IgG subclasses: relationship to clinical aspects of multiple myeloma and frequency distribution among M-components. Scand. J. Haematol. 12, 60. 1974.PubMedCrossRefGoogle Scholar
  65. 65.
    Skipper, H. E. Thoughts on cancer chemotherapy and combination modality therapy. J. Amer. Med. Ass. 230, 1033. 1974.CrossRefGoogle Scholar
  66. 66.
    Sullivan, P. W., Salmon, S. E. Kinetics of tumours growth and regression in IgG multiple myeloma. J.Clin. Invest. 51,1697. 1972PubMedCrossRefGoogle Scholar
  67. 67.
    Velez, R., Beral, V., Cuzick, J. Increasing trends of multiple myeloma mortality in England and Wales; 1950–79; are the changes real? J. Nat. Cancer Inst. 69, 387. 1982.PubMedGoogle Scholar
  68. 68.
    Waldbaum, B., Gelfand, M. Myelomatosis in the Rhodesian African. Tropical Geographical Med. 26, 26. 1974.Google Scholar
  69. 69.
    Waterhouse, J. Muir, C, Shanmugaratnam, K., Powell, J. Cancer incidence in five continents, vol IV. IARC publication No 42. Lyon. 1982.Google Scholar
  70. 70.
    Woodruff, R. K., Wodsworth, J., Malpass, J. S., Tobias, J. S. Clinical staging of multiple myeloma. Brit. 7. Haematol. 42. 199. 1979.CrossRefGoogle Scholar
  71. 71.
    Wurster-Hill, D. H., Mclntyre, O. R., Cornwell, G. G. Chromosome studies in myeloma. Virch. Arch. ’B Cell Path. 29, 93. 1978.Google Scholar

Copyright information

© Jákó János, Budapest 1991

Authors and Affiliations

  • János Jákó
    • 1
  1. 1.1st Department of MedicinePostgraduate Medical SchoolBudapestHungary

Personalised recommendations